]> 2026-04-05T04:14:13+00:00 CR:DOI:9001a5594f91dd6bf04eed25ac6ece98 0 en 2019-11-19T18:49:40Z 2458807.2844907 CR:DOI:9001a5594f91dd6bf04eed25ac6ece98 0 CR:DOI:9001a5594f91dd6bf04eed25ac6ece98# SCITE26d627d92eb7374ed338efb5ec7c735e menzies2018fo <span class="citation">Dick Menzies, Menonli Adjobimey, Rovina Ruslami, Anete Trajman, Oumou Sow, Heejin Kim, Joseph Obeng Baah, Guy B. Marks, Richard Long, Vernon Hoeppner, Kevin Elwood, Hamdan Al-Jahdali, Martin Gninafon, Lika Apriani, Raspati C. Koesoemadinata, Afranio Kritski, Valeria Rolla, Boubacar Bah, Alioune Camara, Isaac Boakye, Victoria J. Cook, Hazel Goldberg, Chantal Valiquette, Karen Hornby, Marie-Josée Dion, Pei-Zhi Li, Philip C. Hill, Kevin Schwartzman, Andrea Benedetti. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. ''New England Journal of Medicine''. 2018;379(5):440-453. [[Digital Object Identifier|doi]]:[http://dx.doi.org/10.1056%2Fnejmoa1714283 10.1056/nejmoa1714283].</span> 10.1056/nejmoa1714283